Cargando…
Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214216/ https://www.ncbi.nlm.nih.gov/pubmed/34147028 http://dx.doi.org/10.1016/j.tranon.2021.101156 |
| _version_ | 1783710017367572480 |
|---|---|
| author | Baidoun, Firas Merjaneh, Zahi Abd-Elhay, Fatma Abd-Elshahed Kamel, Mohamed Gomaa |
| author_facet | Baidoun, Firas Merjaneh, Zahi Abd-Elhay, Fatma Abd-Elshahed Kamel, Mohamed Gomaa |
| author_sort | Baidoun, Firas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8214216 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Neoplasia Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82142162021-06-28 Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma Baidoun, Firas Merjaneh, Zahi Abd-Elhay, Fatma Abd-Elshahed Kamel, Mohamed Gomaa Transl Oncol Commentary Neoplasia Press 2021-06-17 /pmc/articles/PMC8214216/ /pubmed/34147028 http://dx.doi.org/10.1016/j.tranon.2021.101156 Text en © 2021 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Commentary Baidoun, Firas Merjaneh, Zahi Abd-Elhay, Fatma Abd-Elshahed Kamel, Mohamed Gomaa Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma |
| title | Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma |
| title_full | Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma |
| title_fullStr | Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma |
| title_full_unstemmed | Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma |
| title_short | Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma |
| title_sort | comment on: a novel dominant-negative pd-1 armored anti-cd19 car t cell is safe and effective against refractory/relapsed b cell lymphoma |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214216/ https://www.ncbi.nlm.nih.gov/pubmed/34147028 http://dx.doi.org/10.1016/j.tranon.2021.101156 |
| work_keys_str_mv | AT baidounfiras commentonanoveldominantnegativepd1armoredanticd19cartcellissafeandeffectiveagainstrefractoryrelapsedbcelllymphoma AT merjanehzahi commentonanoveldominantnegativepd1armoredanticd19cartcellissafeandeffectiveagainstrefractoryrelapsedbcelllymphoma AT abdelhayfatmaabdelshahed commentonanoveldominantnegativepd1armoredanticd19cartcellissafeandeffectiveagainstrefractoryrelapsedbcelllymphoma AT kamelmohamedgomaa commentonanoveldominantnegativepd1armoredanticd19cartcellissafeandeffectiveagainstrefractoryrelapsedbcelllymphoma |